Rectal toxicity and rectal dosimetry in low-dose-rate 125I permanent prostate implants: A long-term study in 1006 patients

Brachytherapy

Volumn 11, Issue 3, 2012, Pages 199-208

  Keyes, Mira ^a   Spadinger, Ingrid ^a   Liu, Mitchell ^a   Pickles, Tom ^a   Pai, Howard ^b   Hayden, Amy ^a   Moravan, Veronika ^a   Halperin, Ross ^c   McKenzie, Michael ^a   Kwan, Winkle ^b   Agranovic, Alexander ^b   Lapointe, Vince ^a   Morris, W James ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Predictive factors; Prostate brachytherapy; Rectal tolerance; Rectal toxicity

Indexed keywords

IODINE 125;

ACUTE TOXICITY; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; COHORT ANALYSIS; DOSIMETRY; HISTOGRAM; HUMAN; IMPLANT; LEARNING CURVE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECTAL TOXICITY; URINE RETENTION;

ACUTE DISEASE; AGE FACTORS; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CHRONIC DISEASE; COHORT STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIATION INJURIES; RECTUM; TIME FACTORS;

EID: 84859783561     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.05.007     Document Type: Article

References (39)

1. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002, 12:81-94.
2. Cesaretti J.A., Stone N.N., Skouteris V.M., et al. Brachytherapy for the treatment of prostate cancer. Cancer J 2007, 13:302-312.
3. Crook J., Borg J., Evans A., et al. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 patients. Int J Radiat Oncol Biol Phys 2010, [Epub ahead of print].
4. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001, 51:31-40.
5. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:32-43.
6. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995, 32:465-471.
7. Sherertz T., Wallner K., Merrick G., et al. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. Brachytherapy 2004, 3:130-135.
8. Han B.H., Wallner K.E. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications. Int J Cancer 2001, 96:372-378.
9. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001, 50:335-341.
10. Mueller A., Wallner K., Merrick G., et al. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys 2004, 59:1047-1052.
11. Shah J.N., Ennis R.D. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: Use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors. Int J Radiat Oncol Biol Phys 2006, 64:817-824.
12. Gelblum D.Y., Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48:119-124.
13. Waterman F.M., Dicker A.P. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003, 55:342-353.
14. Tran A., Wallner K., Merrick G., et al. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 63:150-154.
15. Morris W.J., Keyes M., Palma D., et al. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:1432-1438.
16. Morris W.J., Keyes M., Palma D., et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009, 73:860-865. discussion 865-867.
17. Keyes M., Miller S., Moravan V., et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009, 73:1023-1032.
18. Hilts M., Spadinger I., Keyes M. Comparison of methods for calculating rectal dose after 125I prostate brachytherapy implants. Int J Radiat Oncol Biol Phys 2002, 53:775-785.
19. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000, 46:221-230.
20. Yu Y., Anderson L.L., Li Z., et al. Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys 1999, 26:2054-2076. [comment].
21. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991, 21:935-939.
22. Keyes M., Pickles T., Agranovich A., et al. 125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004, 60:40-50.
23. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 2006, 64:825-834.
24. Loiselle C.R., Waheed M., Sylvester J., et al. Analysis of the Pro-Qura Database: Rectal dose, implant quality, and brachytherapist's experience. Brachytherapy 2009, 8:34-39.
25. Ghaly M., Wallner K., Merrick G., et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: Morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 2003, 55:1288-1293.
26. Merrick G.S., Butler W.M., Wallner K.E., et al. Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy. Int J Radiat Oncol Biol Phys 2004, 58:68-74.
27. Kang S.K., Chou R.H., Dodge R.K., et al. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 53:99-103.
28. Fiorino C., Vavassori V., Sanguineti G., et al. Rectum contouring variability in patients treated for prostate cancer: Impact on rectum dose-volume histograms and normal tissue complication probability. Radiother Oncol 2002, 63:249-255.
29. Taussky D., Yeung I., Willaims T., et al. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65:358-363.
30. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998, 41:83-92.
31. Crook J., Milosevic M., Catton P., et al. Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. Brachytherapy 2002, 1:66-73.
32. Pinkawa M., Asadpour B., Piroth M.D., et al. Rectal dosimetry following prostate brachytherapy with stranded seeds-Comparison of transrectal ultrasound intra-operative planning (day 0) and computed tomography-postplanning (day 1 vs. day 30) with special focus on sources placed close to the rectal wall. Radiother Oncol 2009, 91:207-212.
33. Waterman F.M., Dicker A.P. Effect of post-implant edema on the rectal dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 45:571-576.
34. Macdonald A.G., Keyes M., Kruk A., et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys 2005, 63:155-163.
35. Cesaretti J.A., Stock R.G., Atencio D.P., et al. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007, 68:1410-1416.
36. Pugh T.J., Keyes M., Barclay L., et al. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Cancer Res 2009, 15:5008-5016.
37. Olive P.L., Banath J.P., Keyes M. Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol 2008, 86:336-346.
38. Elliott K., Wallner K., Merrick G., et al. Medical malpractice of prostate brachytherapy. Brachytherapy 2004, 3:231-236.
39. Waterman F.M., Dicker A.P. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptably low risk of late rectal morbidity?. Int J Radiat Oncol Biol Phys 2003, 57:293-299.